Chief & Presenting Author: Dr.Navjyot kaur

Co Author(s): Prof. Dr.Pradeep Kumar

Abstract

Study design: RCT prospective interventional study
Purpose: To compare the efficacy on Inj Ranibizumab 0.25mg (0.25mg in 0.025ml) versus Inj Aflibercept 1mg (1mg in 0.025ml) in ROP
Methods: it is a prospective RCT in which consent of parents of infants was taken and infants underwent detailed ophthalmic evaluation on each visit after complete dilatation and examination with IDO and RETCAM by qualified VR surgeon/ pediatric ophthalmologist. Infants having ROP stage 2 or more in zone I /II with plus or pre plus disease were injected with either of the Anti- VEGF injections and monitored for regression, progression of disease or adverse effects. Injections were randomised with computer generated software in which patient and examiner were blinded.
Results: Inj Aflibercept was as efficacious as Inj Ranibizumab and showed lower rates of recurrence and needed lesser intervention with re- injection or laser
Conclusion: Inj Aflibercept can be used safely in management of ROP

Full Text